Europe Multiple Sclerosis (Injectables, Infusion, Orals) Market 2011-2017 & 2022

Market potential is more than US$ 5 Billion by 2022. But only more than half this market is expected to be actually achieved.

This huge difference between actual market and unmet market is due to gap between number of patients who require multiple sclerosis drugs and number of patients who are receiving disease modifying therapy.

Orals mode of administration is fast growing disease modifying therapy in the European region. Injectables and infusions multiple sclerosis therapies are steadily losing their ground in the European market.

In the Europe multiple sclerosis market, Germany is the clear winner, but its losing its market share year on year. The other important markets in the European region are France, Italy, Spain and United Kingdom.

Actual Market is the current market which is already present

Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

Key Questions Answered in the Report?

Key Topics Covered:

1 Executive Summary

2 Europe Multiple Sclerosis Patient Numbers (2011-2022)

3 Europe Multiple Sclerosis Market (2011-2022)

4 Europe Multiple Sclerosis Population Share (2011-2022)

5 Europe Multiple Sclerosis Market Share (2011-2022)

6 United Kingdom

7 France

8 Germany

9 Italy

10 Spain

11 Growth Drivers

12 Challenges

13 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/jdcsf6/europe_multiple

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716